(EL) EssilorLuxottica S. A. - Overview
Stock: Lenses, Frames, Sunglasses, Equipment, Instruments
Dividends
| Dividend Yield | 1.62% |
| Yield on Cost 5y | 3.26% |
| Yield CAGR 5y | 38.29% |
| Payout Consistency | 97.9% |
| Payout Ratio | 76.7% |
| Risk 5d forecast | |
|---|---|
| Volatility | 24.5% |
| Relative Tail Risk | -7.59% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.21 |
| Alpha | -13.15 |
| Character TTM | |
|---|---|
| Beta | 0.227 |
| Beta Downside | 0.274 |
| Drawdowns 3y | |
|---|---|
| Max DD | 21.26% |
| CAGR/Max DD | 0.86 |
Description: EL EssilorLuxottica S. A. January 27, 2026
EssilorLuxottica S.A. (EL) designs, manufactures, and distributes a full spectrum of vision-care products-including ophthalmic lenses, frames, sunglasses, contact lenses, and diagnostic equipment-through a portfolio of globally recognized brands such as Essilor, Varilux, Ray-Ban, Oakley, and Persol. The company also supplies optometric tools, digital imaging platforms (e.g., SPECTRALIS, ANTERION), EMR solutions (HEYEX EMR), and lens-edging instruments to independent opticians, large retail chains, e-commerce platforms, and institutional customers worldwide.
Key 2024 metrics illustrate the firm’s scale and growth trajectory: FY 2023 revenue reached €17.1 billion, up 4.2 % YoY, driven by a 6.5 % increase in premium lens sales and a 3.8 % rise in eyewear volume across emerging markets (Latin America and APAC). The global eyewear market is projected to expand at a 5.2 % CAGR through 2028, propelled by aging demographics (the 65+ population in Europe is expected to grow 15 % by 2030) and a surge in myopia prevalence-estimated at 2.5 billion people worldwide-fueling demand for corrective and specialty lenses. Digital-first retail channels now account for roughly 12 % of EL’s total sales, reflecting a sector-wide shift toward online prescription fulfillment.
For analysts seeking a deeper quantitative framework, a quick look at ValueRay’s data visualizations can help surface additional valuation levers and scenario analyses.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 4.67b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 4.46 > 1.0 |
| NWC/Revenue: -0.68% < 20% (prev -1.91%; Δ 1.23% < -1%) |
| CFO/TA 0.16 > 3% & CFO 9.73b > Net Income 4.67b |
| Net Debt (11.26b) to EBITDA (13.11b): 0.86 < 3 |
| Current Ratio: 0.97 > 1.5 & < 3 |
| Outstanding Shares: last quarter (462.0m) vs 12m ago 2.85% < -2% |
| Gross Margin: 62.67% > 18% (prev 0.64%; Δ 6203 % > 0.5%) |
| Asset Turnover: 86.90% > 50% (prev 72.18%; Δ 14.72% > 0%) |
| Interest Coverage Ratio: 16.62 > 6 (EBITDA TTM 13.11b / Interest Expense TTM 420.0m) |
Altman Z'' 2.15
| A: -0.01 (Total Current Assets 11.03b - Total Current Liabilities 11.39b) / Total Assets 61.93b |
| B: 0.25 (Retained Earnings 15.53b / Total Assets 61.93b) |
| C: 0.11 (EBIT TTM 6.98b / Avg Total Assets 61.08b) |
| D: 0.57 (Book Value of Equity 13.52b / Total Liabilities 23.52b) |
| Altman-Z'' Score: 2.15 = BBB |
Beneish M -2.90
| DSRI: 1.08 (Receivables 4.01b/3.05b, Revenue 53.08b/43.47b) |
| GMI: 1.02 (GM 62.67% / 63.78%) |
| AQI: 0.95 (AQ_t 0.68 / AQ_t-1 0.72) |
| SGI: 1.22 (Revenue 53.08b / 43.47b) |
| TATA: -0.08 (NI 4.67b - CFO 9.73b) / TA 61.93b) |
| Beneish M-Score: -2.90 (Cap -4..+1) = A |
What is the price of EL shares?
Over the past week, the price has changed by -1.09%, over one month by -7.97%, over three months by -18.42% and over the past year by -4.25%.
Is EL a buy, sell or hold?
What are the forecasts/targets for the EL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 312.3 | 22.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 273 | 7% |
EL Fundamental Data Overview February 02, 2026
P/E Trailing = 61.9961
P/E Forward = 31.0559
P/S = 4.385
P/B = 3.1178
P/EG = 2.0608
Revenue TTM = 53.08b EUR
EBIT TTM = 6.98b EUR
EBITDA TTM = 13.11b EUR
Long Term Debt = 6.81b EUR (from longTermDebt, last quarter)
Short Term Debt = 4.68b EUR (from shortTermDebt, last quarter)
Debt = 14.05b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.26b EUR (from netDebt column, last quarter)
Enterprise Value = 161.93b EUR (148.13b + Debt 14.05b - CCE 246.0m)
Interest Coverage Ratio = 16.62 (Ebit TTM 6.98b / Interest Expense TTM 420.0m)
EV/FCF = 24.16x (Enterprise Value 161.93b / FCF TTM 6.70b)
FCF Yield = 4.14% (FCF TTM 6.70b / Enterprise Value 161.93b)
FCF Margin = 12.63% (FCF TTM 6.70b / Revenue TTM 53.08b)
Net Margin = 8.80% (Net Income TTM 4.67b / Revenue TTM 53.08b)
Gross Margin = 62.67% ((Revenue TTM 53.08b - Cost of Revenue TTM 19.81b) / Revenue TTM)
Gross Margin QoQ = 63.05% (prev 61.79%)
Tobins Q-Ratio = 2.61 (Enterprise Value 161.93b / Total Assets 61.93b)
Interest Expense / Debt = 1.05% (Interest Expense 147.0m / Debt 14.05b)
Taxrate = 24.16% (463.0m / 1.92b)
NOPAT = 5.29b (EBIT 6.98b * (1 - 24.16%))
Current Ratio = 0.97 (Total Current Assets 11.03b / Total Current Liabilities 11.39b)
Debt / Equity = 0.37 (Debt 14.05b / totalStockholderEquity, last quarter 37.82b)
Debt / EBITDA = 0.86 (Net Debt 11.26b / EBITDA 13.11b)
Debt / FCF = 1.68 (Net Debt 11.26b / FCF TTM 6.70b)
Total Stockholder Equity = 38.87b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.65% (Net Income 4.67b / Total Assets 61.93b)
RoE = 12.02% (Net Income TTM 4.67b / Total Stockholder Equity 38.87b)
RoCE = 15.28% (EBIT 6.98b / Capital Employed (Equity 38.87b + L.T.Debt 6.81b))
RoIC = 11.00% (NOPAT 5.29b / Invested Capital 48.11b)
WACC = 6.23% (E(148.13b)/V(162.18b) * Re(6.75%) + D(14.05b)/V(162.18b) * Rd(1.05%) * (1-Tc(0.24)))
Discount Rate = 6.75% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 0.97%
[DCF Debug] Terminal Value 87.25% ; FCFF base≈5.56b ; Y1≈6.85b ; Y5≈11.67b
Fair Price DCF = 634.6 (EV 305.13b - Net Debt 11.26b = Equity 293.86b / Shares 463.0m; r=6.23% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -3.10 | EPS CAGR: -55.60% | SUE: 0.0 | # QB: 0
Revenue Correlation: 62.23 | Revenue CAGR: 21.55% | SUE: 1.16 | # QB: 1
EPS next Year (2026-12-31): EPS=7.96 | Chg30d=+0.140 | Revisions Net=+14 | Growth EPS=+11.6% | Growth Revenue=+7.5%